InBody Co.,Ltd
041830.KQ - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$621.28B
Close$
$92891.35
62.1% upside
Current Fair Value
62.1% upsideUndervalued by 62.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $621.28 Billion |
|---|---|
| Enterprise Value | $558.09 Billion |
| Annual dividend | $600.00 |
| Dividend yield | 1.29% |
| Earnings per Share | $2423 |
| Beta | 0.62 |
| Outstanding Shares | 13,833,000 |
Return
| Return on Equity | 13.52% |
|---|---|
| Return on Assets | 11.97% |
| Return on Invested Capital | 14.74% |
Valuation & Multiples
| P/E Ratio | 13.09 |
|---|---|
| PEG | 15.07 |
| Price to Sales | 3.0 |
| Price to Book Ratio | 2.29 |
| Enterprise Value to Revenue | 2.11 |
| Enterprise Value to EBIT | 10.72 |
| Enterprise Value to Net Income | 11 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$70.43 B
Consensus analyst estimateNext Earnings Call
Expected Date
November 16, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$71.97 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About InBody Co.,Ltd
266 employees
CEO: Ki-Chul Cha
InBody Co.,Ltd is a global provider of advanced body composition analysis solutions. The company offers an extensive product line, including body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, alo...